The scrutiny centers on an August 2025 disclosure that blindsided investors. Despite previous assurances regarding the Inspire V launch, the company admitted to significant operational failures, including incomplete staff training, delayed software updates for claims processing, and a glut of excess inventory. These revelations forced a massive downward revision of the company's 2025 profit expectations, dropping projections from $2.30 per share to as low as $0.40.

This development follows a securities class action lawsuit against the company and several executives, which recently moved from the Southern District of New York to the District of Minnesota. Investors are now being encouraged to come forward as legal teams examine whether the firm failed to disclose material risks to shareholders. The investigation seeks to determine the extent of corporate malfeasance during a period marked by regulatory and commercial setbacks for the medical device manufacturer.